Victory Capital Management
CPRX

Victory Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Victory Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Sell
132,072
-734,552
-85% -$21.7M ﹤0.01% 1429
2026
Q1 		$21.5M Sell
866,624
-17,981
-2% -$428K 0.01% 847
2025
Q4 		$20.6M Buy
884,605
+467,098
+112% +$10.4M 0.01% 857
2025
Q3 		$8.22M Buy
417,507
+80,703
+24% +$1.66M ﹤0.01% 1171
2025
Q2 		$7.31M Sell
336,804
-202,978
-38% -$4.79M ﹤0.01% 1201
2025
Q1 		$13.1M Buy
539,782
+243,702
+82% +$5.49M 0.01% 955
2024
Q4 		$6.18M Buy
296,080
+4,575
+2% +$98.3K 0.01% 1216
2024
Q3 		$5.8M Buy
291,505
+15,996
+6% +$297K 0.01% 1244
2024
Q2 		$4.27M Sell
275,509
-3,281
-1% -$51.1K ﹤0.01% 1272
2024
Q1 		$4.44M Buy
278,790
+21,067
+8% +$317K ﹤0.01% 1264
2023
Q4 		$4.33M Sell
257,723
-53,632
-17% -$733K ﹤0.01% 1261
2023
Q3 		$3.64M Buy
311,355
+17,697
+6% +$237K ﹤0.01% 1266
2023
Q2 		$3.95M Buy
293,658
+4,709
+2% +$67.8K ﹤0.01% 1243
2023
Q1 		$4.79M Sell
288,949
-3,977
-1% -$65.6K 0.01% 1206
2022
Q4 		$5.45M Sell
292,926
-73,066
-20% -$1.12M 0.01% 1185
2022
Q3 		$4.7M Buy
365,992
+670
+0.2% +$7.94K 0.01% 1260
2022
Q2 		$2.56M Sell
365,322
-14,884
-4% -$109K ﹤0.01% 1402
2022
Q1 		$3.04M Buy
380,206
+271,172
+249% +$1.92M ﹤0.01% 1373
2021
Q4 		$739K Sell
109,034
-37,297
-25% -$245K ﹤0.01% 1968
2021
Q3 		$775K Sell
146,331
-46,249
-24% -$253K ﹤0.01% 1961
2021
Q2 		$1.11M Sell
192,580
-9,890
-5% -$51K ﹤0.01% 1861
2021
Q1 		$933K Buy
202,470
+59,611
+42% +$237K ﹤0.01% 1946
2020
Q4 		$477K Buy
142,859
+30,811
+27% +$104K ﹤0.01% 2107
2020
Q3 		$333K Buy
112,048
+23,614
+27% +$92.3K ﹤0.01% 2124
2020
Q2 		$409K Buy
88,434
+7,724
+10% +$34.7K ﹤0.01% 2052
2020
Q1 		$311K Buy
80,710
+14,077
+21% +$57.8K ﹤0.01% 2006
2019
Q4 		$250K Buy
66,633
+23,929
+56% +$112K ﹤0.01% 2257
2019
Q3 		$227K Buy
+42,704
New +$228K ﹤0.01% 2179

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management's CPRX Position: Q2 2026 in Review

Victory Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 85% in Q2 2026, selling an estimated $21.7M and leaving 132,072 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Victory Capital Management first reported a position in CPRX in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.5M in Q1 2026. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Victory Capital Management held 132,072 shares of Catalyst Pharmaceutical worth $4.15M as of Q2 2026.
  • Victory Capital Management sold 734,552 Catalyst Pharmaceutical shares in Q2 2026, an estimated $21.7M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1429 holding.
  • Victory Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Catalyst Pharmaceutical position peaked at $21.5M in Q1 2026.
  • 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.